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Pulmonary surfactantThis work focuses on the interaction of mycolic acids (MAs) and two antimycobacterial compounds
(Rifabutin and N′-acetyl-Rifabutin) at the pulmonary membrane level to convey a biophysical perspective of
their role in disease. For this purpose, accurate biophysical techniques (Langmuir isotherms, Brewster angle mi-
croscopy, and polarization-modulation infrared reﬂection spectroscopy) and lipid model systems were used to
mimic biomembranes: MAsmimic bacterial lipids of theMycobacterium tuberculosis (MTb)membrane, whereas
Curosurf® was used as the human pulmonary surfactant (PS) membranemodel. The results obtained show that
high quantities ofMAs are responsible for signiﬁcant changes on PS biophysical properties. At the dynamic inspi-
ratory surface tension, high amounts of MAs decrease the order of the lipid monolayer, which appears to be a
concentration dependent effect. These results suggest that the amount of MAs might play a critical role in the
initial access of the bacteria to their targets. Both molecules also interact with the PS monolayer at the dynamic
inspiratory surface. However, in the presence of higher amounts ofMAs, both compounds improve the phospho-
lipid packing and, therefore, the order of the lipid surfactantmonolayer. In summary, this work discloses the pu-
tative protective effects of antimycobacterial compounds against theMAs induced biophysical impairment of PS
lipidmonolayers. These protective effects aremost of the times overlooked, but can constitute an additional ther-
apeutic value in the treatment of pulmonary tuberculosis (Tb) andmay provide signiﬁcant insights for the design
of new and more efﬁcient anti-Tb drugs based on their behavior as membrane ordering agents.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Tuberculosis (Tb) is an infectious disease caused by Mycobacterium
tuberculosis (MTb) and represents a major health concern around the
world [1]. Nearly nine million new cases are estimated each year, two
million of them being fatal due to the increment of multidrug resistant
Tb [2,3]. The eradication of Tb is difﬁcult sinceMTb lipidic envelope con-
fers impermeability to antibiotics and ability to withstand unfavorable
conditions [1,3,4]. For this reason, the treatment of Tb is associated to
a multidrug combination therapy for at least 6 months [1]. Therefore,; DPPC, Dipalmitoylphospha-
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l rights reserved.to improve the therapeutic compliance, new and more effective drugs
are urgently needed [1,5], requiring their development new approaches
to understand the mechanism of action of classical therapies.
In pulmonary Tb, which is the most common manifestation of Tb,
the inhaled MTb encounters the pulmonary surfactant (PS) before
reaching its target (the alveolar macrophage) [6]. Besides being a phys-
iological barrier to the entrance of bacteria in the body, PS is from a bio-
physical point of view, a lipid monolayer containing hydrophobic and
hydrophilic proteins. This compressible monolayer possesses a funda-
mental role in decreasing alveoli surface tension, which has proved to
be essential to facilitate respiratory work and prevent alveoli collapse
[7,8]. The recent accepted mechanism for this latter crucial function
states that, during expiration, the ﬂuid lipids and proteinswith less abil-
ity to sustain high surface pressures are squeezed out from the PS
monolayer, leading to an enrichment of the ﬁlm with less ﬂuid lipids
[9]. During respiratory movements the lost lipids and proteins are
stored in surface-associated “reservoirs” at the adjacent interface
being available for further re-adsorption [10–12].
The MTb cell wall is extremely rich in lipids, and this high lipid con-
tent is consistent with the bacteria primary location nearby the air/
water interface of PS monolayers. The lipids from MTb cell wall have
897M. Pinheiro et al. / Biochimica et Biophysica Acta 1828 (2013) 896–905been further implicated in the PS dysfunction that causes the typical
symptoms of pulmonary Tb, namely the decrease of pulmonary compli-
ance manifested as breathing difﬁculty and, consequently, as an in-
creased respiratory work [1,13]. In this regard, Chimote and coworkers
have previously proposed a biophysical explanation to some of the
symptoms observed in pulmonary Tb. According to these authors, the
pulmonary symptoms might be due to the biophysical impairment of
the lung surfactant function due to the interfacial presence of mycobac-
terial lipids [14]. In another study performed by the same authors, it was
demonstrated by atomic force microscopy (AFM) that mycobacterial
lipids could aggregate within PS monolayers, resulting in a disturbed
monolayer surface activity. The authors also suggested that this could
be a mechanism of lung surfactant dysfunction in pulmonary Tb [13].
Wang et al. also studied the inhibitory effects of mycobacterial lipids in
bovine and calf lung surfactant models and concluded that the bacterial
lipids inhibited the monolayer surface activity in both PS models [15].
Besides the importance of PS as a lung reservoir for MTb, the lungs
are also organs of anti-Tb drugs bioaccumulation, possibly due to their
distribution at the PS lipid level. In this context, it is important to pursue
biophysical studies to unveil the interplay of antimycobacterial com-
pounds and MTb with PS lipid monolayers, as these studies might pro-
vide additional and important insights about the therapeutic role of the
drugs protecting PSmonolayers from the impairment effects of themy-
cobacterial lipid [1,16].
To our knowledge, there is only one experimental study reported in
the literature concerning the interaction of anti-Tb drugs and PS. This
study performed by Chimote et al. evaluates the interactions between
DPPC, themain compound of the PS, and the anti-Tb drugs (isoniazid, ri-
fampicin and ethambutol). The results of this study have shown that the
antimycobacterial compounds improve the surface parameters of the PS
model, which correlates with a putative protective role of these
antimycobacterial compounds of the PS biophysical integrity in vivo [17].
Beyond the abovementioned studies, the knowledge of the biophys-
ical effects of both MTb membrane lipids and anti-Tb drugs is still
scarce, particularly the information related with their accessibility to
the PS lipidmonolayer. In this context, our study provides the ﬁrst com-
prehensive survey of the implications caused by different amounts of
mycobacterial lipids in a natural lung surfactant that mimics the
human PS, and it is also the ﬁrst study on the interaction of RFB (RFB)
and N′-acetyl-Rifabutin (RFB2) with PS monolayer in the presence
and absence of mycobacterial lipids.
RFB is a second-line drug used in Tb treatment [1,5]. Despite being
a second-line drug, RFB has shown to be more efﬁcient than ﬁrst-line
drugs, such as rifampicin [18]. Moreover, RFB therapeutic value is in-
creasing due to its beneﬁcial effect on the newly diagnosed multidrug
resistant Tb and in the prevention of the disseminatedMycobacterium
avium complex infection in HIV positive cases [18,19]. For these men-
tioned reasons, and given the excellent penetration capacity of RFB in
cells, as well as the accumulation of this drug in the pulmonary tissue,
the biophysical study proposed herein may prove important to broad-
en the knowledge of this drug mechanism of action or to conduct the
design of more effective derivates. In this context, our newly synthe-
sized RFB derivate is also object of the current study (Fig. 1). In com-
parison to RFB, RFB2 shows better in vitro and in vivo therapeutic
index, thereby being a promising drug for the clinical application in
Tb treatment [5]. RFB and RFB2 were both used in this work at
concentrations that were reported as effective against MTb and
Mycobacterium avium complex and as non-toxic against Vero cells [5].
The biophysical approach of our study required not only a rational
choice of the anti-Tb drugs, but also a careful choice of lipids and lipid
models to mimic the biological environment encountered by these
drugs. In this regard, the mycolic acids (MAs) have been chosen to
mimic the MTb membrane since they are the main components of
the MTb cell wall, being indispensable for its structural integrity
[20,21]. MAs are α-alkyl-β-hydroxyl high molecular weight fatty
acids. Each molecule consists of a hydrophobic long saturated2-alkyl branch and a hydrophilic head group (containing the groups
COOH and OH) as shown in Fig. 1 [20,22,23]. MAs occur in the cell
wall of MTb as variable mixtures of different classes (α-MA,
methoxy-MA and keto-MA) that exhibit different conformations in
the PS monolayers [24–26]. Both keto- and methoxy-MA produce
the so-called “W” conformation, with the alkyl chains folded to give
four parallel arms with the carbonyl and methoxy groups hydrated
by water molecules in the surface layer [22]. However, independently
of the surface pressures applied, keto-MA retains the compact
W-shape, while methoxy-MA adopts extended structures [22]. In
the case of α-MA, the most abundant form of MAs, as the surface
pressure is increased by compression, the molecules apparently
change from the compact W-shape to extended conformations with
two hydrocarbon chains [22,27,28]. Curosurf®, a PS porcine extract,
was elected as the PS model because it presents a composition and
biophysical properties similar to the human PS, being used as replace-
ment therapy in several human disorders related to lung's injury,
such as the respiratory distress syndrome [9,29]. Despite the similar-
ities with the human PS, Curosurf® possesses a different amount of
components and lacks neutral lipids and hydrophilic proteins [29].
The main component of Curosurf® is dipalmitoylphosphatidylcholine
(DPPC) (Fig. 1) (47% w/w). The other prevailing lipids are zwitterionic
such as lysophosphatidylcholine (LPC), sphingomyelin (SM), phos-
phatildylethanolamine (PE), and a signiﬁcant amount of negatively
charged lipids (5.7–9.6% w/w) namely phosphatidylglycerol (PG),
phosphatildylinositol (PI) and phosphatilserine (PhS) [29,30]. The hy-
drophobic proteins present in Curosurf® are surfactant protein B
(SP-B) (0.4% w/w) and SP-C (0.7% w/w), which extensively interact
with the surfactant phospholipids and increase their ability to efﬁcient-
ly decrease the surface tension [9,29]. These proteins are cationic due to
the positively charged arginine and lysine amino acids present in their
composition [31,32].
In summary, besides unveiling the mechanisms of interaction of
antimycobacterial compounds (RFB and RFB2) with PS (Curosurf®),
this work can contribute to identify novel biophysical mechanisms that
explain the therapeutic effect of these antimycobacterial compounds,
hence allowing the future development of more effective drugs that
are able to protect the PSmonolayer from the biophysical impairment ef-
fect induced by the MAs. Additionally, and besides many studies have
proven the importance of SP-B and SP-C on the function of the lung activ-
ity [10,11,31,33–35], this is the ﬁrst report of the effects of MAs and
antimycobacterial compounds in SP-B and SP-C studied in situ.
2. Materials and methods
2.1. Materials
RFBwas isolated fromMycobutin® and further puriﬁed as described
previously [5]. RFB2 was obtained from RFB, using a selective acylation
of the secondary amine [5]. MAs were purchased from BioClot GmbH,
Germany, and used without any further puriﬁcation. Curosurf® was
purchased from Angelini Farmacêutica Lda, Portugal, and was used as
originally supplied. Sodium chloride, monopotassium phosphate and
dipotassium phosphate (99% pure) were purchased from Panreac®.
Chloroform and methanol were used as co-spreading solvents. The
subphase used, phosphate buffer 100 mM (pH 7.4; 100 mM of sodium
chloride), was prepared from ultrapure water, produced by Millipore
Milli-Q unit (resistivity=18.2 MΩ cm).
2.2. Methods
2.2.1. Langmuir trough
Two different troughs models, a KN-1005 (KSV Instruments Ltd,
Helsinki, Finland) and NIMA 601(Nima Technology, Coventry, En-
gland) were equipped with two symmetrical barriers and a Wilhelmy
type dynamometric system using a strip of ﬁlter paper. KN-1005 is
Fig. 1. Chemical structures of DPPC (A), MAs (B), RFB (C) and RFB2 (D).
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NIMA 601 is about 400 mL in subphase volume with a total area
close to 600 cm2. KN-1005 was used in PM-IRRAS experiments. Due
to its larger capacity and area, that allows the compensation of pres-
sure restrictions imposed by the smaller trough [29], NIMA 601 was
used to obtain the represented isotherms.
2.2.2. Film spreading
All ﬁlms were prepared by spreading samples on the phosphate
buffer subphase. Films were spread by deposition of tiny droplets
of samples uniformly on the air–water interface, using a 250 μL
microsyringe. Curosurf® was spread from 0.2 mg/mL chloroform-
extracted solutions. MAs were spread from 0.2 mg/mL chloroform:
methanol-extracted solutions (9:1 v/v). After spreading, solvent was
allowed to evaporate for 15 min prior to ﬁlm compression. The ef-
fect of antimycobacterial compounds was evaluated by spreading
Curosurf®, Curosurf®:MAs (9:1 w/w) and Curosurf®:MAs (1:1 w/w)
monolayers on a phosphate buffer with a known concentration of RFB
and RFB2 (0.118 μM and 0.225 μM respectively).
2.2.3. Film compression
All spread ﬁlms were compressed at a rate of 20 cm2/min (at a
much slower rate than the respiratory movements, due to exper-
imental limitations). During compression, surface pressure–area
isotherms (π/A) were recorded until the maximum compression pos-
sible in our trough (i.e. at the maximum value of≈50 mN/m of com-
pression). The absolute molecular area (Å2/molecule) of DPPC was
used to express the compression isotherms. All experiments were
performed in an atmosphere with 100% relative humidity at 21 °C.
2.2.4. Brewster angle microscopy
Brewster angle microscopy (BAM) images were obtained from a
I-Elli 2000 apparatus (supplied by Nanoﬁlm Technologies, Goettingen,
Germany) using a Nd:YAG diode laser, which can be recorded with a
lateral resolution of 2 μm. The image processing procedure included a
geometrical correction of the image, as well as a ﬁltering operation toreduce interference fringes and noise. Furthermore, the brightness of
each image was scaled to improve contrast.
2.2.5. Polarization-modulation infrared reﬂection spectroscopy
Polarization-modulation infrared reﬂection spectroscopy (PM-IRRAS)
was performed using a KSV PMI 550 instrument (KSV Instruments Ltd,
Helsinki, Finland) recording the spectra every 2 mN/m from 0 to
40 mN/m. The Langmuir trough was set up so that the light beam
reached themonolayer at a ﬁxed angle of incidence of 80°. The incoming
light was continuouslymodulated between s and p polarization at a high
frequency. This allowed the simultaneous measurements of spectra for
the two polarizations, and their difference provides surface-speciﬁc in-
formation, while their sum provides the reference spectrum (buffer
with or without antimycobacterial compound). In this work, PM-IRRAS
was elected due to the advantages over the conventional IRRAS mode,
namely the independence of modulated reﬂectivity of the isotropic ad-
sorption from the vapor or bulk water, overcoming the problem of the
surrounding water vapor [36,37].
2.2.6. Parameters studied from the surface pressure–area Langmuir
isotherms
A variety of systems have been used for determining the surface
activity of surfactant materials derived from the lungs, including
Langmuir trough and captive bubble surfactometer [38–41]. In compar-
ison to the Langmuir trough, the captive bubble surfactometer reveals a
much lower compressibility, extremely low surface tensions and a
moderated hysteresis if the ﬁlm collapse is avoided [42]. However,
over the past few years, the evolution of Langmuir trough designs
allowed it to sustain high surface pressures which, coupled with spec-
troscopy and image techniques such as BAM and IRRAS, constitutes a
valuable system to visualize the morphology and the characterization
of the PS monolayers [9,40]. Langmuir isotherms give information
about the lipid phases and the phase transitions, which are both depen-
dent on the temperature, the pressure, and the pH [43,44]. The param-
eters studied from the surface pressure–area (π/A) Langmuir isotherms
were: the minimum area per molecule; the hysteresis and the
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area occupied for one molecule in the surface layer and it indicates
the molecular packing and the interactions between the monolayer
components. This parameter was determined by extrapolation of a
line tangent to the condensed region. Hysteresis was acquired by the
monolayer compression/decompression isotherms and corresponds to
the difference between compression and decompression areas [32].
The cycle of compression/decompression was performed to mimic
the expiration/inspiration movements, respectively. Elastic modulus
(Cs−1)was calculated from theπ/A isothermsby the following equation:
Cs
−1 ¼−A dπ=dAð Þ;where A is the area per lipidmolecule, and π is the
surface pressure. Cs−1 describes the relationship between the surface
pressure increase and the area per molecule decrease. A higher value
of Cs−1 is indicative of a less compressible monolayer [44,45].
3. Results and discussion
3.1. Comparison of compression isotherms
Fig. 2 represents the pressure–area (π/A) isotherm of Curosurf®.
In the recorded isotherm three biophysical states of the PS monolayer
can be identiﬁed: zone A, zone B and zone C [43]. The molecular na-
ture of these three regions is further discussed in the BAM and
IRRASmeasurements. The zone A of the Curosurf® isotherm, between
0 and 5 mN/m, represents a less ordered region with high compress-
ibility, typical of a liquid-expanded (LE) phase of the monolayer [12].
In the LE phase, phospholipid acyl chains have a considerable degree
of rotational freedom. The zone B, between 5 and 40 mN/m, corre-
sponds to a less compressible ﬁlm and represents the coexistence of
two phases: liquid-condensed (LC) and LE phase. The Curosurf® iso-
therm did not show an apparent phase transition plateau but the ap-
pearance of a plateau region (zone C) starting at ≈43 mN/m is
noticeable. In this region, before and after reaching the plateau, natu-
ral surfactant ﬁlms have lower compressibility due to the removal of
the LE phase from the ﬁlm by the “squeezing-out” of the proteins and
ﬂuid lipids like PGs, that leave the interface and consequently lead to
the monolayer enrichment with DPPC [12,46]. In this plateau region
the isotherm undergoes a monolayer-to-multilayer transition pla-
teau, in which π only increases slowly with signiﬁcant ﬁlm compres-
sion [9]. The appearance of the plateau region in the 40–50 mN/m
range is controversially discussed. Some authors pointed this plateau
region as the ﬁlm collapse [47,48]. However, other authors report a
ﬁrst plateau region within this pressure range and describe it as the
transition of monolayer-to-multilayers [9,49]. They showed that thisFig. 2. Surface pressure (π/A) isotherm of Curosurf®.characteristic plateau is followed by a rapid increase in the surface
pressure that leads to a second plateau (the ﬁlm collapse) [9]. Indeed,
in Fig. 2 it is possible to observe that after the plateau region (π above
47 mN/m) a pressure increment starts to happen, possibly leading to
the monolayer collapse, which was not reached due to the maximum
compression possible in our trough. In vivo, during the inhalation–
expiration cycle, the lung surfactant monolayer experiences surface
tension values between 30 and 0 mN/m [50]. However since TB starts
with the inhalation of MTb, the equilibrium inspiratory surface tension
(correspondent to a surface pressure of 40 mN/m) is the most relevant
in this work. Additionally, in the pulmonary TB, due to surfactant deﬁ-
ciency and/or dysfunction, a pronounced elevated alveolar surface
tension might occur [51].
The comparison between the Curosurf®:MAs (9:1 w/w) and
Curosurf®:MAs (1:1 w/w) isotherms (Fig. 3) indicates that the effect
of MAs on the biophysical properties of Curosurf® is concentration de-
pendent. For lower concentrations of MAs, the biophysical effects are
negligible as the isotherms Curosurf®:MAs (9:1 w/w) and Curosurf®
are almost superimposed. The interactions of the Curosurf® monolayer
with higher amounts of MAs are pronounced and occur at all the differ-
ent regions of the isotherm. Higher amounts of MAs shift the isotherm
to larger molecular areas, i.e. causing a monolayer expansion. At the
zone C, the transition of monolayer-to-multilayer happens at the same
pressure as for lower amounts ofMAs, and occurs at slightly lower pres-
sures when compared to the Curosurf® monolayer in the absence of
MAs, meaning that in the presence of MAs the PS monolayer is less sta-
ble. Moreover the MAs contain negatively charged carboxyl groups at
the physiological pH (predicted using MarvinView® 5.4.1.1 software
from ChemAxon), and thus electrostatic repulsions with the PS head
groups might happen, contributing to the monolayer expansion. Van
der Waals interactions may also take place, between the mycolate
alkyl chains and the PS acyl chains. Furthermore, the MAs chain-
length asymmetry might create spaces through part of the lipid ﬁlm
thickness into which alkyl chains of associated PS phospholipids may
ﬁt, justifying the earlier transition of the PS to a more condensed
phase when the MAs are present [27,52].
The antimycobacterial compounds (RFB and RFB2) clearly change
the isotherm of Curosurf® (Fig. 3). The interactions with the
antimycobacterial compounds are higher at the LE region (zone A)
since the lower lipid density in this region facilitates the drug interaction
and insertion in comparison to the LC region (zone C). Despite the veryFig. 3. Surface pressure (π/A) isotherms of Curosurf® (black line), Curosurf®:MAs 9:1
w/w (red line), Curosurf®:MAs 1:1 w/w (green line), Curosurf®:RFB (0.118 μM) (dark
blue line), Curosurf®:RFB2 (0.225 μM) (light blue line), Curosurf®:MAs (1:1 w/w):RFB
(0.118 μM) (purple line) and Curosurf®:MAs (1:1 w/w):RFB2 (0.225 μM) (yellow
line).
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and B, it can be observed that RFB2 interacts more extensively with the
PS model. This might be due not only to the higher concentration of
RFB2 used, but also to the presence of an acetyl group that confers a
bulkier and an extra lipophilic group that is more prone to interact
with the lipids/proteins of the PS. Moreover, the isotherm of
Curosurf®:RFB2 presents a smaller plateau region at π≈5–10 mN/m,
that is not observed in the case of Curosurf®:RFB, which represents
the LE and LC phase coexistence and a more visible phase transition.
The extra acetyl group of RFB2 must be once more a reason for this dif-
ference, conferring a higher surface activity that for this reason demon-
strates increased ability to spread at the interface. The higher interaction
of RFB2 with the PS model, comparing with RFB, might justify its previ-
ously reported higher in vivo efﬁcacy [5]. This was further conﬁrmed by
the second compression isotherm of the PS model after the decompres-
sion, which has revealed to be more similar to the ﬁrst compression
when in presence of RFB2 than in presence of RFB (data not shown). It
is possible to recognize that in the zone C the antimycobacterial com-
pounds interact differently with the Curosurf®. In the case of RFB, the
transition of monolayer-to-multilayer starts at π≈38 mN/m. For RFB2
the transition begins at π≈42 mN/m, which is slightly lower compared
to the Curosurf® but higher than RFB. Since this transition occurs when
the proteins and the PG lipids are “squeezed out” from themonolayer to
form themultilayers [53] and at smaller pressures when in the presence
of RFB, it is predictable that, in comparison to RFB2, RFB's interactions
with PG and proteins are higher. According to the distribution of the
charged species, predicted by MarvinView® 5.4.1.1 software from
ChemAxon, at the physiological pH RFB has a higher contribution of
thepositively charged species (due to the ionization of thepiperidine ni-
trogenwith a pKa9.5) [54], possibly promoting stronger electrostatic in-
teractions with the negatively charged phospholipids (like PG).
The effect of the antimycobacterial compounds in the presence of
both Curosurf® and MAs was also tested (Fig. 3). The presence of the
antimycobacterial compounds and the higher quantities of MAs
shifted the Curosurf® isotherm to higher areas, these changes occur
in all the different regions and especially at the lower pressures for
the same reasons already described. Furthermore, the transition of
monolayer-to-multilayers occurs at the same pressures previously
described in the isotherms of Curosurf® with the antimycobacterial
compounds and in the absence of MAs.
The Amin determined for Curosurf® was 101 Å2/molecule. The dif-
ference between compression and expansion isotherms is small, con-
sidering that it was only performed at the ﬁrst cycle, which is
essential for an efﬁcient PS [32,43]. The maximum Cs−1 calculated
for Curosurf® was 439 mN/m (Table 1), close to the value for pure
DPPC [44,55]. As expected, the Cs−1 maximum values were found for
surface pressures ranging from 20 to 30 mN/m, as well in the plateau
region from 40 to 50 mN/m (data not shown) [55]. The Amin of
the Curosurf® in the presence of the MAs is clearly higher. This de-
notes that MAs remain at the interface, probably within the PS
components, under compression. The integration of MAs in the PSTable 1
Minimum area per lipid molecule, elastic Modulus and hysteresis of the Langmuir
Curosurf®, Curosurf®:MAs 9:1 w/w, Curosurf®:MAs 1:1 w/w, Curosurf®:RFB
(0.118 μM), Curosurf®:RFB2 (0.225 μM), Curosurf®:MAs (1:1 w/w):RFB (0.118 μM)







Curosurf® 101±5 439±10 4013±100
Curosurf®:MAs9:1 135±5 441±10 4698±100
Curosurf®:MAs1:1 138±5 398±10 7470±100
Curosurf®:RFB 198±5 877±10 6278±100
Curosurf®:RFB2 183±5 735±10 4955±100
Curosurf®:MAs:RFB 424±5 1350±100 8182±100
Curosurf®:MAs:RFB2 481±5 1330±100 8348±100monolayer can occur as a result of the interactions of the MAs with
the head groups or with the phospholipid tails of the lipid PS compo-
nents. The interactions of the MAs with the PS head groups possibly
happen by means of hydrogen bonds and electrostatic interactions,
and explain the increase of the Amin of the Curosurf® in the presence
of the MAs, as these interactions cause a large area requirement of the
head group and, to optimize their van der Waals interactions, force
the chains to be tilted in the condensed phase [44]. If the interactions
with the phospholipid tails also take place, they would be more pro-
nounced in the case of higher amounts of MAs. However, the value of
the Amin is very similar in the presence of the two different propor-
tions of the MAs studied. The intercalation of the MAs residues within
the components of the PS, in order to compensate the chain-length
differences and to produce higher packing density, may be the re-
sponsible for the very similar values of the Amin observed by higher
amounts of MAs [52]. Additionally, a non-mixed monolayer may
also be formed due to the lack of correlation between the MAs
amount and the Amin and also due to the collapse pressure obtained,
which is the same independently of the MAs concentration. Besides
analyzing the changes induced by the MAs in the Amin of the PS
monolayer, it is also important to study the effect of the MAs in
other parameters, such as the hysteresis behavior of the PS monolay-
er. A good hysteresis behavior results from a small difference be-
tween the compression and expansion isotherms of the monolayer
[32]. In the opposite case of higher hysteresis the interfacial work of
breathing is increased [43]. MAs increase the hysteresis value of the
PS monolayer and this increase reaches signiﬁcantly higher values
(≈46%) with the higher amount of MAs. This ﬁnding is consistent
with the deleterious effect caused by the MTb in the interfacial
work of breathing. Regarding the effects of MAs in the Cs−1 of the PS
monolayer, a biphasic behavior is observed. Lower amounts of MAs
did not change the Cs−1 whereas higher amounts of MAs are respon-
sible for a more compressible monolayer with a Cs−1 value lower than
that obtained for the PS model in the absence of MAs. Consistent with
our work, previous studies of mixed monolayers of MAs and phos-
pholipids having a choline head group (the main phospholipids pres-
ent in our PS model) reported a monolayer expansion effect (i.e.
monolayer becomes more compressible) [14,52]. The Cs−1 values
suggest that the MAs are integrated within the phospholipids of
the monolayer, consequently causing a monolayer expansion that
seems to be dependent of the MAs amount. The increase in the
compressibility of the PS monolayer, as observed in the presence
of MAs, has a negative connotation for the PS surface activity, as it
indicates the sudden destabilization of the PS ﬁlm that is related
to a poorly packed surfactant and leads to an increased breathing
work [51].
Both antimycobacterial compounds shift the Amin of Curosurf® to
higher values, indicating a strong interaction of the antimycobacterial
compounds with the PS. The Amin is higher in the presence of RFB
comparing to RFB2. Although RFB2 is bulkier, this antimycobacterial
compound might be located nearer to the phospholipids tails due to
the presence of one extra acetyl group. RFB shallower location at
the head groups of PS phospholipids is consistent with the higher
Amin, given the large area requirement of the head groups. Both
antimycobacterial compounds increase the hysteresis of the PS,
being the hysteresis increase caused by RFB2 smaller (≈19%) com-
pared to the hysteresis increase caused by RFB (≈36%). Overall,
both RFB and RFB2 interact extensively with Curosurf® forming less
compressible monolayers as observed by the increase of Cs−1 values.
Furthermore, the interaction of the antimycobacterial compounds
with “squeezed-out” components of the PS (lipids like PG and pro-
teins) seems to happen especially for RFB, due to the lower values
of the pressure of transition from monolayers to multilayers in the
presence of this antimycobacterial compounds.
In the presence of MAs both antimycobacterial compounds shift the
Amin of Curosurf® to even higher values than that observed when the
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pounds with the MAs might form a bulky complex that then interacts
with the negatively charged head groups of the PS justifying the great
changes observed in the Amin. Contrastingly to the effect of the
antimycobacterial compounds on Curosurf®, observed in the absence
of MAs, in the presence of higher amounts of MAs, RFB2 elevates the
Amin to higher values than RFB. This might be attributed to a closer in-
teraction of the complex MAs and RFB2 with the head groups of the
PS and consequently the greater area requirements at the head group
region of the PS monolayer translate into higher Amin values. Both
antimycobacterial compounds, in the MAs presence, increase the hys-
teresis of the PS (≈51%), with no noticeable differences between the ef-
fects of each antimycobacterial compound. Although in the presence of
MAs the antimycobacterial compounds form less compressible PS
monolayers, the increase in the Cs−1 values was similar to that observed
when the antimycobacterial compounds were interacting with the PS
monolayer in the absence of MAs.
3.2. BAM
BAM is a powerful tool that enables the visualization of the mor-
phological changes that occur during the compression of the mono-
layers. Moreover, BAM also gives some information on the ﬂuidity
of the ﬁlm in relation to the geometry of the domains observed at
the water interface [56]. The contrast in BAM images is due to local
differences in the monolayer refractivity index, caused by differences
in local molecular density or packing [10,12,57].
The morphologies of Curosurf®, Curosurf®:MAs (9:1 w/w),
Curosurf®:MAs (1:1 w/w), Curosurf®:RFB, Curosurf®:RFB2, Curosurf®:
RFB:MAs (1:1 w/w) and Curosurf®:RFB2:MAs (1:1 w/w) at constant π
of about 4, 24 and 40 mN/m (zones A, B and C) of the ﬁrst compression
are shown and were directly observed by BAM (Fig. 4).
The domains of Curosurf® appear at pressures above ≈24 mN/m
(transition from LE to LC) and become larger with the compression, as
it can be conﬁrmed by the image obtained at 47 mN/m (Fig. 4B). For
intermediate pressures (24≤π≤40 mN/m) the BAM images show a
homogenous size distribution of circular shape lipid domains (see
inset of ≈24 mN/m in Fig. 4A). For π>40 mN/m the lipid domainsA B C D
Fig. 4. BAM images of Langmuirmonolayers of Curosurf® (5.3 mN/m–221 Å2/molecule; 23 mN
248 Å2/molecule; 25 mN/m–173 Å2/molecule; 45 mN/m–80 Å2/molecule), Curosurf®:M
115 Å2/molecule), Curosurf®:RFB (0.118 μM) (4.4 mN/m–404 Å2/molecule; 26.5 mN/m–2
488 Å2/molecule; 24.4 mN/m–220 Å2/molecule; 43.6 mN/m–152 Å2/molecule, Curosurf®:MA
45.4 mN/m-143 Å2/molecule) and Curosurf®:MAs (1:1 w/w):RFB2 (0.225 μM) (6.4 mN/m–80are noncircular and have ramiﬁed shape domains (see inset of
47 mN/m in Fig. 4A). These lipid domains with a starry aspect are
very characteristic of this natural PS [29]. Furthermore, the BAM
image obtained in the plateau region (Fig. 4A) conﬁrms that the
monolayer collapse was not reached since the domains' coalescence
was not observed. The BAM image appears mainly gray, which is con-
sistent with a high fraction of solid phase. The white spots that appear
on the top are attributed to the ﬂuid phase material that is pushed out
of the interface when the transition of monolayer-to-multilayer oc-
curs and a DPPC enriched ﬁlm is formed [12,57]. The presence of
low amounts of MAs is enough to promote a signiﬁcant change in
the PS lipid domains. The transition of LE to LC occurs at π≈3 mN/m
(data not shown), and for π≈4 mN/m, small elliptical domains with a
very small size can be observed (Fig. 4C). The size and number of
these lipid domains increase with the pressure. For all the different re-
gions, the domains have an elliptical shape. Higher amounts ofMAs pro-
mote higher differences in the lipid domains' size and morphology. For
π≈4 mN/m some brighter points appear with a heterogeneous distri-
bution along the predominant LE region (Fig. 4D). These brighter points
might be aggregates of MAs with phospholipids, such as PI [14]. Al-
though beingmore pronounced for lower pressures, the brighter points
are present at all the different pressures evaluated. For intermediate
pressures (24≤π≤40 mN/m) the lipid domains are not as visible, but
it is possible to recognize the presence of some small and elliptical do-
mains. The brighter points are also present, but in a smaller amount
andwith amore homogenous distribution (data not shown). For higher
pressures, the presence of smaller aggregates can be observed. In the
plateau region there is an enrichment of the monolayer in DPPC and
the few aggregates are probably due toMAs' collapse [22,23,27,52]. Fur-
thermore, the BAM image, for π≈40 mN/m (Fig. 4D), conﬁrms the
MAs' collapse, probably because MAs are less surface active in compar-
ison to the Curosurf® components, and thus the PS and MAs mixed
monolayer reaches the collapse earlier at smaller surface pressures [14].
The BAM images of Curosurf® in the presence of antimycobacterial
compounds reveal the existence of very bright regions that can be asso-
ciated with RFB and RFB2 local clusters with high refractive index, indi-
cating the formation of the antimycobacterial compound at the
interface (Fig. 4E and F). In the case of RFB, the antimycobacterialE F G H I
/m–179 Å2/molecule; 47 mN/m–64 Å2/molecule), Curosurf®:MAs 9:1 w/w (6.1 mN/m–
As 1:1 w/w (3.7 mN/m–332 Å2/molecule; 25.6 mN/m–225 Å2/molecule; 45 mN/m–
20 Å2/molecule; 47 mN/m–74 Å2/molecule, Curosurf®:RFB2 (0.225 μM) (6.1 mN/m–
s (1:1 w/w):RFB (0.118 μM) (6.6 mN/m-600 Å2/molecule; 24.7 mN/m-346 Å2/molecule;
4 Å2/molecule; 24 mN/m–378 Å2/molecule; 45 mN/m–164 Å2/molecule).
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while the number of lipid domains increases there is a decrease in their
size, emerging bright regions inside the domains. Therefore, at interme-
diate and higher pressures, spherical domains presenting inner small
bright points that correspond to the antimycobacterial compound
(RFB or RFB2) can be observed. Moreover, in the case of Curosurf® in
the presence of RFB2, and especially at higher pressures, it is possible
to identify domains without the antimycobacterial compound, possibly
due to a “squeezing-out” of the RFB2. This is consistent with the smaller
value of the Amin obtained for RFB2 in comparison to RFB.
The presence of the antimycobacterial compounds and higher
amounts of MAs showed the occurrence of irregular and small lipid
domains at intermediate and higher pressures (Fig. 4G and H). The
BAM domains do not contain the characteristic bright spots of
antimycobacterial compound clusters possibly due to the binding of
the RFB or RFB2 to MAs when higher amounts of MAs are present at
the PSmonolayer. However, someﬁlamentary structures that are possi-
ble aggregates could be observed, particularly in the presence of RFB2
(see inset of≈24 mN/m in Fig. 4I). The appearance of these structures
conﬁrms the occurrence of immiscibility between the different com-
ponents of the monolayer [14]. At lower pressures (π≈4 mN/m),
and in the presence of RFB, the monolayer seems so have some con-
densed structures with ﬁlamentary morphology, whereas in the
presence of RFB2, the monolayer is still in the LE phase. Therefore,
in the presence of RFB2, the condensed domains of the monolayer
occur only at intermediate and higher pressures and occupy larger
areas than the obtained in the presence of RFB. However, upon com-
pression (π≈40 mN/m), RFB seems to be present at the interface in
higher proportions, as observed from the brighter domains of the
monolayer (Fig. 4G).
3.3. PM-IRRAS
The PM-IRRAS of lipid/protein monolayers ﬁlms, in situ at the air/
water interface, provides unique information about the molecular
structure and orientation of the ﬁlm's constituents [36,58]. The re-
sults in three different regions of the isotherm (4 mN/m, 24 mN/m
and 40 mN/m) are presented in Table 2.
When analyzing the PM-IRRAS band characteristic of the lipidic
portion of the PS monolayer (Curosurf®), the frequency of the
bands C=O and PO2− were, as expected, higher for π=40 mN/m
than for smaller pressures (4 mN/m). Higher wavenumbers, of the
carbonyl υ(C=O) stretching band (1734 cm−1 at π=4 mN/m and
1736 cm−1 at π=40 mN/m, Table 2) and the asymmetric phosphate
υas(PO2−) stretching vibration (1223 cm−1 at π=4 mN/m and an ad-
ditional band at 1249 cm−1 at π=40 mN/m, Table 2), correspond toTable 2
Vibrational wavenumbers (asymmetric phosphate, carbonyl, asymmetric methylene) of the
(0.118 μM), Curosurf®:RFB2 (0.225 μM), Curosurf®:MAs (1:1 w/w):RFB (0.118 μM) and C
lower (π=4 mN/m), intermediate (π=24 mN/m) and higher pressure (π=40 mN/m).









Curosurf® 1223 1734 2926 1216
Curosurf®:MAs9:1 1220 1729 2916 1232
Curosurf®:MAs1:1 1259 1745 2920 1245
1263
Curosurf®:RFB 1211 1735 2923 1222
1247 1250
Curosurf®:RFB2 1249 1717 2921 1229
Curosurf®:MAs:RFB 1213 1744 2914 1216
1242
Curosurf®:MAs:RFB2 1226 1736 2919 1231the less-hydrated head groups characteristic of the LC phase that oc-
curs at higher pressures [59]. Moreover, the dehydration of the head
groups occurs not only by the compression and expulsion of water
molecules at π≈40 mN/m, but also by the transition of
monolayers-to-multilayers that starts roughly at this pressure, lead-
ing to the “squeezing-out” of negative lipids of the monolayer and
promotion of the dehydration process. Contrastingly, at an intermedi-
ate pressure (24 mN/m), the value of υas(PO2−) stretching vibration
appears to be rather low (1216 cm−1) and one would expect that
the compression from 4 to 24 mN/m would increase the frequency
of these bands as a consequence of water molecules being expelled
from the head groups upon compression. However, it has been
reported that this rather unexpected low values of υas(PO2−) may
occur because the phosphate moiety of the phospholipid molecules,
is thought to be involved in a strong intermolecular hydrogen bond-
ing with the glycerol hydroxyl group of neighboring molecules and
these hydroxyl groups may partially mimic the solvation properties
of water [59]. With the compression from π≈4 mN/m to 40 mN/m,
the CH2 asymmetrical stretching band shifts from 2926 cm−1 to
2915 cm−1 (Table 2). Hence, the decrease in the asymmetric CH2
stretching frequency, as the monolayer is compressed, indicates the
formation of all-trans conformation (characteristic of LC phase) and
the loss of gauche conformers (characteristic of LE phase) [36,60,61].
The PM-IRRAS results endorse that the interaction of the MAs with
the PS model is dependent of the bacterial lipid concentrations. Lower
amounts of MAs do not seem to signiﬁcantly interact with the head
groups of the phospholipids. Independently of the amount of MAs
and comparing with the PS model, the CH2 stretching frequencies
are lower at low pressures, suggesting a more ordered lipid state
which might be due to the MAs residues that may be positioned with-
in the phospholipids chains, thereby increasing the lipid packing. The
CH2 stretching is especially affected for lower concentrations of MAs,
being the monolayer, in agreement to the BAM observations, con-
densed at all the three pressures studied. Although being more or-
dered at lower pressures, when the pressure increases (π≈24 and
≈40 mN/m), the monolayer of the PS model containing higher
amounts of MAs is less ordered comparing to Curosurf® in the ab-
sence of MAs. Furthermore, higher frequency values obtained for
the PO2− and C=O stretching indicate that higher amounts of MAs
are responsible for the production of a less hydrated monolayer.
Both antimycobacterial compounds interact with the phospholipid
head groups of the PS model, as can be conﬁrmed by the shift induced
in the PO2− and in the C=O bands. For RFB, at the lower surface pres-
sures, the band contour of PO2− consists of at least two overlapped fea-
tures, at 1211 and at 1247 cm−1, probably corresponding to dihydrated
and monohydrated phosphate groups, respectively. The band positionLangmuir Curosurf®, Curosurf®:MAs 9:1 w/w, Curosurf®:MAs 1:1 w/w, Curosurf®:RFB












1730 2916 1223 1736 2915
1249
1728 2916 1236 1731 2916
1262
1746 2920 1259 1744 2920
1731 2918 1255 1741 2916
1741 2916 1253 1739 2915
1744 2918 1260 1744 2918
1733 2918 1237 1740 2917
Fig. 5. PM-IRRAS spectra of Curosurf® (black line), Curosurf®:MAs 9:1 w/w (red line),
Curosurf®:MAs 1:1 w/w (green line), Curosurf®:RFB (0.118 μM) (dark blue line),
Curosurf®:RFB2 (0.225 μM) (light blue line), Curosurf®:MAs (1:1 w/w):RFB
(0.118 μM) (purple line) and Curosurf®:MAs (1:1 w/w):RFB2 (0.225 μM) at π=
40 mN/ (yellow line).
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tween the drug and the negative lipids, containing a large number of OH
groups (e.g. PG and possibly PI) thatmaymimic the solvation properties
of water. The pressure increment shifts the PO2− band to higher
wavenumbers, which is consistent with the drug being “squeezed
out” from the monolayer. The interactions of the antimycobacterial
compounds with the PS monolayer also occur at the fatty acid tail
level, as suggested by the shift in the CH2 wavenumbers. At lower pres-
sures the interaction with the fatty acid tails seems to be less pro-
nounced for RFB than for RFB2. However, both antimycobacterial
compounds produce a more ordered monolayer on account of the
lower wavenumbers of the CH2 stretching obtained in the presence
of the antimycobacterial compounds. The increase in the lipid or-
der might be due to a higher packing effect by the formation
of antimycobacterial compound aggregates at the interface. For in-
termediate and higher pressures the interactions between the
antimycobacterial compounds and the PS monolayer are not so pro-
nounced and RFB forms a less ordered monolayer than the obtained
with Curosurf® alone or Curosurf® with RFB2.
Regarding the effect of RFB on PSmonolayers containingMAs, it is
possible to observe from PM-IRRAS data that the drug interacts with
the phospholipid head groups at all the assayed pressures. At lower
pressures the small frequency value of PO2− stretching, points to
a high degree of hydrogen bonding between the drug and the
negatively charged lipids, and possibly with the carboxyl and hy-
droxyl groups of MAs. With the pressure increase, the vibration
wavenumbers of the PO2− are shifted to higher values. This indicates
that the established hydrogen bonds are reduced, possible due to the
fact of RFB being “squeezed out” from the monolayer. The resulting
monolayer is condensed at all pressures but is less ordered at inter-
mediate and higher pressures in comparison with the PS model in
the absence of drug and mycolic acids. The effect of RFB2 on the PS
monolayer containing high amounts of MAs is very similar to that
observed for RFB. The main difference is that the frequency value of
PO2− stretching for pressures of ≈4 mN/m is not so low, being the
electrostatic interactions with the PS negatively charged lipids not
so pronounced. The resultant monolayer is also condensed at the dif-
ferent pressures; however at smaller pressures and in the presence
of higher amounts of MAs, RFB seems to form an even more ordered
monolayer.
It is well known that the secondary structure of the SP-B and SP-C is
related with the normal functions of these hydrophobic proteins, and
changes in their structure might have a negative implication by induc-
ing changes in the PS surface activity [62]. Accordingly, besides analyz-
ing the lipidic portion of the PSmonolayer, we have also used PM-IRRAS
to study the secondary structure of the SP-B and SP-C at the dynamic in-
spiratory tension. In this regard we have focused on the analysis of the
amide I band (1650 cm−1), which is described as more sensitive to
estimate the conformation and orientation of the protein compared to
the amide II band (1550 cm−1) [56,63]. The amide I band can therefore
give information regarding the secondary structure of the proteins
and according to the band position allows the identiﬁcation of β-turns
(1662–1682 cm−1), α-helices (1645–1662 cm−1), and β-sheets
(1613–1637 cm−1). If the band appears as two components: one at
the β-sheet position and another as a shoulder at 1682–1710 cm−1 it
is indicative of an antiparallel β-sheet. The parallel β-sheet is predicted
to have higher frequency for the lower component [62,64,65]. The dis-
order of random coils (unstructured) occurs at the same wavenumbers
of the α-helices (1637–1650 cm−1), originating from the former
broader and less intense bands compared to the α-helices [62,64,66].
Fig. 5 shows the effects of antimycobacterial compounds and MAs in
the secondary structure of the PS proteins given by the IRRAS amide I
band for π≈40 mN/m.
For the PS model, the amide I band exhibits for this pressure two
overlapping bands attributed to the α-helices and β-sheet. Although
the native SP-B and SP-C have α-helical segments, the secondarystructure is dependent of the isolation and puriﬁcation procedures.
Therefore, in order to conclude about the inﬂuences of other com-
pounds in the secondary structure of the PS proteins, it is important to
determine the conformation of the proteins in the conditions studied
[43]. For this pressure, MAs decrease the amount of proteins at the in-
terface, as stated by the lower intensity values of their amide I band.
Higher amounts of MAs showed a more pronounced change in the sec-
ondary structure of the PS proteins. Electrostatic interactions with the
proteins seem to happen, especially in the case of the presence of higher
amounts of MAs as more pronounced changes are observed in the
amide I stretching band. Moreover, for lower and higher amounts of
MAs a decrease in absorbance centered around the α-helices region
was observed. The β-turn conformation is conﬁrmed by the presence of
one peak at the 1681 cm−1 for lower amounts of MAs and 1678 cm−1
for higher amounts of MAs. Additionally, β-sheets are also formed but
their amount is inferior comparing to the PSmodel. The interactions be-
tween RFB and the proteins of the PS model also seem to be less pro-
nounced than the interactions between RFB2 and the proteins,
probably due to the higher electrostatic repulsions veriﬁed in the for-
mer case. Although a decrease in the protein amount at the interface
is conﬁrmed in the RFB's presence, the secondary structure of the pro-
teins does not seem to suffer a signiﬁcant change as the amide I peaks
assigned are similar to the ones of the Curosurf®. In the case of RFB2
interacting with the PS monolayer, the absorbance for amide I is cen-
tered around 1631, 1675 and 1700 cm−1 for all pressures, which is in-
dicative of antiparallel β-sheet and β-turn conformations. When both
antimycobacterial compounds and MAs are present, the PS proteins
exhibit β-turns and antiparallel β-sheets. In the case of RFB, the an-
tiparallel β-sheet has a perpendicular orientation to the air/water
interface.
4. Conclusions
The PS is one of the ﬁrst barriers of the lung and interacts with in-
haled agents as the etiologic agent of Tb. The initial interactions of the
surfactant components with the MTb may contribute to the uptake of
the bacteria in alveolar epithelial cells and macrophages and subse-
quent initiation of adaptive immunity in the lung [43,67]. In this work,
the biophysical interactions of theMTb and the antimycobacterial com-
pounds with a PS model were evaluated, using an in vitro model of
Langmuir monolayers. The results allowed to conclude that the amount
of the MAs plays an important role in the impairment of the PS control
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amount of these deleterious lipids the lipid order of the PS monolayer
is reduced. Since the monolayer molecular aggregation is related to
the function of permeability control via the molecular packing [32,68],
this phenomenon might be the ﬁrst step in providing to the bacteria
an easier access to the target, the alveolar macrophage. Hence, the
lipid order decrease triggered by the high amount of MAs may contrib-
ute to the biophysical impairment of the protective PS monolayer with
the consequent entrance of the bacteria into the cells due to a higher fa-
cility in reaching the alveolar macrophages. Moreover, the order de-
crease of the PS model is prejudicial to the lung activity, and larger
quantities of MAsmight largely contribute to the respiratory failure ob-
served in chronic steps of the disease. The compounds also cause
changes in the biophysical parameters of the PS, contributing RFB
and RFB2 to a less compressible and more ordered monolayer. More-
over, both antimycobacterial compounds protect the PS from the lip-
id disordering effect caused by the higher amounts of MAs. The
antimycobacterial compounds increase the order of the PS in the
presence of higher amounts of MAs, and this packing increment might
protect the lungs from the entry of the bacteria, being this a
possible alternative explanation for the therapeutic efﬁciency of these
antimycobacterial compounds. RFB2 also contributes to the appearance
of condensed domains on the PS monolayer at very low pressures,
which is indicative of an increment of the lipid order. This compound
might aggregate and form monolayers, which, concerning the use of
this antimycobacterial compound as a replacement therapy of atelecta-
sis areas, could be very interesting in the future. Additionally, it is well
known that a PS in normal conditions has selected properties such as
high surface pressure, no hysteresis, and high compressibility of the
monolayer [32,43]. The inﬂuence of the MAs and the antimycobacterial
compounds in these parameters were established in order to under-
stand the negative effects of the MAs in these parameters as well as
the inﬂuence of both compounds. The MAs seem to increase the respi-
ratory work, especially when they are present in higher quantities.
The higher increment of the hysteresis associated with the lipid order
decrease suggests that the bacteria could escape into the water phase,
and once in the alveolar systems, be able to reach the alveolar macro-
phages and the bloodstream [1,53]. The secondary structure of the pro-
teins changes upon interaction with: MAs, RFB, RFB2 and with both
compounds when MAs are present. Since the antimycobacterial com-
pounds and theMAs alter the structure of the proteins in the plateau re-
gion, the way how the material is removed from the interface also
changes and this could have negative effects in the lung function
and alter the normal breathing process [53,62]. Moreover, the hystere-
sis of the PS monolayer when both antimycobacterial compounds
and MAs are present does not increase relatively to the hysteresis
of the PS monolayer when MAs are present in the absence of the
antimycobacterial compounds, suggesting that the RFB and its derivate
might reduce the amount of bacteria that is able to reach the alveolar
macrophages and the bloodstream.Acknowledgements
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